Intervention

Apatinib

ClinicalTrials.gov intervention label

Clinical trials64

Recruiting5

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World StudyNCT07640048 · 2025-05-04

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain MetastasisNCT06418594 · 2024-10-10

SNF Platform Study of HR+/ HER2-advanced Breast CancerNCT05594095 · 2022-12-30

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 2022-11-01

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)NCT05447702 · 2022-11-01

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung CancerNCT07031154 · 2025-06-30

NOT_YET_RECRUITING

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung CancerNCT06786312 · 2025-01-25

NOT_YET_RECRUITING

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast CancerNCT07371910 · 2024-06-12

ACTIVE_NOT_RECRUITING

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast CancerNCT06447623 · 2024-06-11

ACTIVE_NOT_RECRUITING

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast CancerNCT05759572 · 2023-03-01

ACTIVE_NOT_RECRUITING

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and ChemotherapyNCT04878107 · 2022-03-15

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line ImmunotherapyNCT04670913 · 2021-06-28

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerNCT04506242 · 2020-09-15

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung AdenocarcinomaNCT04459078 · 2020-08-26

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M MutationNCT03758677 · 2020-08-01

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.NCT04335006 · 2020-07-14

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）NCT04659785 · 2020-07-01

Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLCNCT04425135 · 2020-07-01

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）NCT04453930 · 2020-06-08

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBCNCT04303741 · 2020-03-25

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLCNCT04133337 · 2019-11-01

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapyNCT03742193 · 2019-08-11

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung CancerNCT03777124 · 2019-07-11

Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based RegimenNCT03792503 · 2019-02-01

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine CancerNCT04239443 · 2019-01-30

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLCNCT03389256 · 2018-12-30

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast CancerNCT03775928 · 2018-12-18

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast CancerNCT03735082 · 2018-11-01

Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid CarcinomaNCT03709953 · 2018-10-19

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast CancerNCT03982485 · 2018-10-16

ACTIVE_NOT_RECRUITING

Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung CancerNCT03651219 · 2018-09-08

This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of TreatmentNCT03650738 · 2018-09-01

Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast CancerNCT03243838 · 2018-08-01

A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung CancerNCT03547804 · 2018-05-31

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard TherapyNCT03417895 · 2018-04-20

Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast CancerNCT03457467 · 2018-03-15

Apatinib in Combination With Docetaxel for Patients With Advanced NSCLCNCT03411967 · 2018-02-01

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBCNCT03394287 · 2018-01-10

Study of Apatinib as the Maintenance Therapy in Advanced Lung AdenocarcinomaNCT03376737 · 2017-10-12

Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast CancerNCT03348098 · 2017-09-06

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast CancerNCT03254654 · 2017-08-16

Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer PatientsNCT03190239 · 2017-07-15

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLCNCT03201146 · 2017-06-27

Apatinib in Neoadjuvant Therapy for Patients With Breast CancerNCT03580395 · 2017-06-01

APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLCNCT03164694 · 2017-05-20

The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung CancerNCT03129698 · 2017-04-11

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)NCT03083041 · 2017-03-13

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer PatientsNCT03075462 · 2017-03-09

Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung CancerNCT02980809 · 2017-03-01

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)NCT03416231 · 2016-11-30

Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast CancerNCT03086785 · 2016-11-24

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.NCT03384511 · 2016-09-30

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast CancerNCT02768415 · 2016-06-01

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR MutationsNCT02824458 · 2016-06-01

Tarceva With or Without Apatinib in the Advanced Lung AdenocarcinomaNCT02704767 · 2016-06-01

Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate CancerNCT02998242 · 2016-05-10

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)NCT02878057 · 2016-05-01

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung CancerNCT02780778 · 2016-05-01

The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung CancerNCT02733107 · 2016-03-01

Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical StudyNCT02702323 · 2016-03-01

Common conditions

Leading sponsors

Fudan University7 Jiangsu HengRui Medicine Co., Ltd.6 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences2 Chinese Academy of Medical Sciences2 Hebei Medical University Fourth Hospital2 Hunan Cancer Hospital2 Junling Li2 Peking Union Medical College Hospital2 Sichuan Cancer Hospital and Research Institute2 Sun Yat-sen University2 The First Affiliated Hospital of Xiamen University2 The First Hospital of Jilin University2 Tianjin Medical University Cancer Institute and Hospital2 West China Hospital2

Trial status mix

UNKNOWN35

COMPLETED12

ACTIVE_NOT_RECRUITING5

RECRUITING5

WITHDRAWN3

NOT_YET_RECRUITING2

TERMINATED2

Phase mix

PHASE253

PHASE39

PHASE14

PHASE42

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.